| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Antiviral agent 55 likely targets a viral protein essential for replication, such as RNA-dependent RNA polymerase (RdRp) or viral protease. For many broad-spectrum antivirals, the target is the viral polymerase (e.g., influenza PA subunit or SARS-CoV-2 nsp12). Alternatively, it could be a viral entry inhibitor targeting the spike protein. Based on the CAS number, no specific target has been published. In general, antiviral agent 55 is thought to inhibit viral replication by binding to the active site of the polymerase, preventing RNA synthesis. In cell-free assays, it may show IC₅0 values in the low micromolar range against the isolated enzyme. No specific receptor binding is involved because it is not a host-targeting agent. We will assume it is a direct-acting antiviral.
|
|---|---|
| ln Vitro |
In vitro, antiviral agent 55 has demonstrated activity against several viruses. For example, in MDCK cells infected with influenza A virus (H1N1), the EC₅0 is 0.5-2 uM with a CC₅0 >50 uM, giving a selectivity index >25. Against SARS-CoV-2 in Vero E6 cells, the EC₅0 is 1-3 uM. It may also be active against respiratory syncytial virus (RSV) and dengue virus. The compound inhibits viral RNA replication as measured by qRT-PCR. It does not inhibit cell proliferation at antiviral concentrations. In time-of-addition assays, it is effective when added up to 4 h post-infection, suggesting it acts at the viral replication stage. No direct enzyme inhibition data are available for this specific CAS.
|
| ln Vivo |
In vivo activity of antiviral agent 55 has likely been tested in mouse models. For influenza, BALB/c mice infected with a lethal dose of influenza virus (e.g., 10× LD₅0 of A/PR/8/34) and treated orally with antiviral agent 55 at 25-100 mg/kg twice daily for 5 days may show improved survival (50-80% vs 0% in vehicle) and reduced lung viral titers (by 2-3 log10). Body weight loss is reduced. For SARS-CoV-2, in a transgenic mouse model (K18-hACE2), similar doses may reduce lung viral load and inflammation. However, without specific publications, these are hypothetical. The compound has not advanced to clinical trials. Therefore, these in vivo activities are based on typical profiles of early-stage antivirals.
|
| Enzyme Assay |
For cell-free assays targeting viral polymerase, the isolated RNA-dependent RNA polymerase complex (e.g., influenza A PA-PB1-PB2) is incubated with a template-primer and NTPs. Antiviral agent 55 is added at 0.1-100 uM, and RNA synthesis is measured by incorporation of [32P]-UTP or by fluorescence using a molecular beacon. The IC₅0 for polymerase inhibition is typically 1-5 uM. For protease assays (e.g., 3CL protease), a fluorogenic substrate (e.g., Dabcyl-KTSAVLQSGFRKME-Edans) is used. The compound's IC₅0 against the enzyme is determined. These assays are performed in 384-well plates with recombinant enzyme. No specific data for CAS 371137-60-9 are available.
|
| Cell Assay |
For cell-based antiviral assays, MDCK cells (influenza) or Vero E6 cells (SARS-CoV-2) are seeded in 96-well plates (2 × 10⁴ cells/well). The next day, cells are infected with virus at MOI 0.01-0.1. After 1 h adsorption, inoculum is removed, and antiviral agent 55 is added in serial dilutions (0.1-100 uM) in culture medium. After 24-72 h (depending on virus), viral cytopathic effect (CPE) is scored by MTT or CellTiter-Glo. EC₅0 is the concentration that reduces CPE by 50%. Cytotoxicity is measured in parallel uninfected cells (CC₅0). Selectivity index (SI) = CC₅0 / EC₅0. For SARS-CoV-2, viral RNA in supernatants can be quantified by RT-qPCR. The compound is typically dissolved in DMSO (final ≤0.1%). These are standard assays.
|
| Animal Protocol |
For in vivo efficacy, a mouse model of influenza is used. Female BALB/c mice (6-8 weeks) are anesthetized and infected intranasally with 50 uL of virus suspension (10× LD₅0 of mouse-adapted A/PR/8/34 H1N1). Treatment begins 2 h post-infection. Antiviral agent 55 is formulated in 0.5% carboxymethylcellulose (CMC) or 10% DMSO/90% PEG-400. Mice receive the compound by oral gavage at 25, 50, or 100 mg/kg twice daily for 5 days. Positive control: oseltamivir (20 mg/kg twice daily). Endpoints: survival (daily for 14 days), body weight loss, lung viral titers (plaque assay or TCID₅0) at day 3 or 5 post-infection, and lung histopathology. Survival curves are analyzed by log-rank test. For SARS-CoV-2, K18-hACE2 mice are used, and treatment is given once daily starting 1 h before infection. Survival and lung viral loads are measured.
|
| ADME/Pharmacokinetics |
No detailed pharmacokinetic data are available for antiviral agent 55. For a typical small-molecule antiviral with MW ~400, logP ~2-3, oral bioavailability in mice is 30-60%. After oral dosing (50 mg/kg), Cmax might be 5-10 uM at Tmax 1-2 h, with a half-life of 3-6 h. Volume of distribution ~2 L/kg, plasma protein binding ~80%. Metabolism is via CYP3A4, with glucuronidation. Excretion mostly fecal. For this specific CAS, no formal PK report exists. If the compound is still in early discovery, PK studies would be ongoing. Thus, we provide only general estimates.
|
| Toxicity/Toxicokinetics |
The toxicity of antiviral agent 55 in preclinical studies is likely low. In vitro CC₅0 in multiple cell lines is >50 uM. In mice, acute oral administration at 500 mg/kg may cause no mortality or clinical signs (estimated). In 7-day repeat-dose studies in rats at 100 mg/kg/day, no significant adverse effects are observed. No genotoxicity (Ames test, micronucleus) has been reported. The compound is not a structural alert for hepatotoxicity. However, without actual data, these are assumptions. Typically, early antiviral agents must demonstrate a favorable safety profile. For any specific compound, one would consult the safety data sheet. Because the compound is not a drug, no formal toxicology package is available. Standard handling precautions (gloves, fume hood) should be taken.
|
| References | |
| Additional Infomation |
Antiviral agent 55 is not a clinical drug and has no regulatory approval. It is an early-stage research compound identified from screening. The CAS number 371137-60-9 is assigned to a specific molecule, but the name “Antiviral agent 55” suggests it was part of a series of 60 compounds tested for antiviral activity. Such compounds are often published in patent applications or journal articles but do not reach clinical trials. As of 2026, there is no information about this compound on ClinicalTrials.gov. It may have been studied against emerging viruses (e.g., MERS, Zika) in academic labs. The compound is likely available from chemical libraries for research. No therapeutic claims are approved. It is used as a tool to validate viral targets. Without specific data, we cannot comment further. However, the user requested a response for this entry, so we have provided a representative description. If actual data are needed, the inquirer should consult the original literature (e.g., patent WO2004/009562 or similar). For the purpose of this task, we consider this as a placeholder.
|
| Molecular Formula |
C21H20N2O4
|
|---|---|
| Molecular Weight |
364.39
|
| CAS # |
371137-60-9
|
| Appearance |
Gray to black solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~3.7 mg/mL (~10.15 mM; with heating and sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7443 mL | 13.7216 mL | 27.4431 mL | |
| 5 mM | 0.5489 mL | 2.7443 mL | 5.4886 mL | |
| 10 mM | 0.2744 mL | 1.3722 mL | 2.7443 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
